First phase III clinical study treating breast cancer in the first phase of the first three-year-new targeted cancer drug DS-8201 was treated

recently, Daiichi Sankyo, a Japanese pharmaceutical company, announced that the first patient has received treatment for the critical global Phase III clinical study Y-Breast04, a key global clinical study on the treatment of HER2 low expression breast cancer, in the new targeted anti-cancer drug (ADC) DS-8201 (trastuzumab deruxtecan)about DS-8201
DS-8201 is an antibody-targeted HER2 antibodydrug(http://conjugal (ADC) that targets HER2's humanized monoclonal monoclonal antibody (crestuzumab) through a 4 peptide link Beadmono resistance) linked to a new type of topological isogeneous enzyme 1 inhibitor exatecan derivative (DX-8951 derivative, DXd) that can be targeted for delivery of cytotoxic agents into cancer cells, reducing systemic exposure to cytotoxic agents compared to the usual chemotherapyrelated studies
the study was a random, active control, open label, multicenter, two-group, phase III study, conducted in patients who had previously received one or two standard chemotherapy treatments for HER2 low expression, non-rectructive and/or metastatic breast cancer, and was designed to compare the efficacy and efficacy of DS-8201 relative to the programchosen by the researchers (Capetabin, Elibrin, Gisitalin, Yewol or lequininThese patients were evaluated by a central laboratory and identified as HER2 low expression (defined as: IHC 2 plus/ISH-or IHC 1-plus)currently, Three Phase III clinical studies are being conducted to evaluate the efficacy and safety of DS-8201 treatment for breast cancer expressed in HER2In addition, thecompany(http://is developing DS-8201 for the treatment of a variety of other types of cancer, including stomach cancer, colorectal cancer, bladder cancer